Last reviewed · How we verify
Proparacaine drops 0.05%
At a glance
| Generic name | Proparacaine drops 0.05% |
|---|---|
| Sponsor | London Health Sciences Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa (NA)
- Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion (NA)
- Proparacaine vs Placebo for Corneal Injuries (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Proparacaine drops 0.05% CI brief — competitive landscape report
- Proparacaine drops 0.05% updates RSS · CI watch RSS
- London Health Sciences Centre portfolio CI